The Company

Kynos is a clinical stage biopharmaceutical company focusing on the development of novel treatments for patients suffering from acute and chronic inflammatory diseases. It is owned by
Dr. Falk Pharma GmbH and therefore a part of the Falk Group.

Kynos leverages many years of research on KMO inhibitors conducted by its founders and collaborators. The lead molecule KNS366 has moved into clinical development.